Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2012 Oct 25;13(1):48–54. doi: 10.1016/j.clml.2012.07.009

Table 1.

Survey Results of Determination of Suboptimal Response to Therapy (Questions 33 and 24)a

Response Optiona General, n (%) Case Based, n (%)
No HR at 30 Months 223 (44) 276 (54.4)
Less Than CHR at 3 Months 155 (30.6) 181 (35.7)
Less Than CHR at 6 Months 204 (40.2) 215 (42.4)
No Cytogenetic Response at 6 Months 217 (42.8) 256 (50.5)
Less Than PCyR at 6 Months 143 (28.2) 178 (35.1)
Less Than PCyR at 12 Months 165 (32.5) 194 (38.3)
Less Than CCyR at 12 Months 183 (36.1) 183 (36.1)
Less Than CCyR at 18 Months 132 (26.0) 160 (31.6)
Less Than MMR at 18 Months 192 (37.9) 192 (37.9)
Loss of CHR or CCyR Any Time 201 (39.6) 206 (40.6)
Loss of MMR Any Time 158 (31.2) 148 (29.2)

Abbreviations: CCyR, complete cytogenetic response; CHR = complete hematologic response; HR = hematologic remission; MMR, major molecular response; PCyR, partial cytogenetic response.

a

Multiple answers were allowed.